Oxidative Medicine and Cellular Longevity / 2016 / Article / Tab 1

Research Article

Glutathione as a Biomarker in Parkinson’s Disease: Associations with Aging and Disease Severity

Table 1

Participant demographics.

CNS uptake

Mean (SD)
Phase IIb

Mean (SD)
Combined

Mean (SD)

Gender
 Male11 (73%)22 (51%)33 (57%)
 Female4 (27%)21 (49%)25 (43%)
Age, years 65.5 (11.2)62.2 (10.8)62.2 (10.8)
Disease severity
 Years since PD diagnosis6.15 (6.24)3.54 (2.2)4.26 (3.9)
 UPDRS78.9 (15.4)67.8 (9.5)70.7 (12.2)
 PRO-PD869 (334)804 (422)821 (399)
Hoehn & Yahr
 19 (20.9%)9 (15.5%)
 1.56 (14.0%)6 (10.3%)
 26 (40%)17 (39.5%)23 (39.7%)
 2.54 (27%)7 (16.3%)11 (19.0%)
 35 (33%)4 (9.3%)9 (15.5%)

UPDRS: Unified Parkinson’s Disease Rating Scale; PRO-PD: Patient-Reported Outcomes in Parkinson’s Disease.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.